X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The collaboration will explore the potential therapeutic benefits of combination therapy of BBT-877, a novel ATX inhibitor, with anti-PD-1 immunotherapy for the treatment of NSCLC in patients harboring KRAS and P53 (KP) mutations who are resistant to anti-PD-1 blockade.
Lead Product(s): BBT-877,Undisclosed
Therapeutic Area: Oncology Product Name: BBT-877
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emory University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2024
Details:
The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer. The two entities will conduct preclinical studies to evaluate the potential of BBT-877 in enhancing anti-tumor immunity.
Lead Product(s): BBT-877
Therapeutic Area: Oncology Product Name: BBT-877
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Colorado School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2024
Details:
BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
Bridge Biotherapeutics and Boehringer Ingelheim have mutually agreed on the termination of the Collaboration and License Agreement entered into in July 2019 to develop BBT-877 for the treatment of idiopathic pulmonary fibrosis and various fibrotic diseases.
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
